{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:22:15Z","timestamp":1767993735715,"version":"3.49.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ucl.2016.04.010","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T05:38:15Z","timestamp":1469684295000},"page":"393-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments"],"prefix":"10.1016","volume":"43","author":[{"given":"Charles","family":"Welliver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Essa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2016.04.010_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Low urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1464-410X.2003.04459.x","article-title":"The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study","volume":"92","author":"Boyle","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(03)00358-0","article-title":"Lower urinary\u00a0tract symptoms and erectile dysfunction: co-morbidity or typical \u2018\u2018Aging Male\u2019\u2019 symptoms? Results of the \u2018\u2018Cologne Male Survey\u2019\u2019","volume":"44","author":"Braun","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.urology.2004.01.039","article-title":"Obstructive lower urinary tract symptoms correlate with erectile dysfunction","volume":"63","author":"Elliot","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib5","first-page":"2257","article-title":"Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms","volume":"169","author":"Vallancien","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib6","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/bmj.324.7345.1059","article-title":"Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial","volume":"324","author":"Brookes","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ucl.2016.04.010_bib7","first-page":"546","article-title":"Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate","volume":"150","author":"Price","year":"1993","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0169-328X(98)00287-3","article-title":"Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels","volume":"63","author":"Smith","year":"1999","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.ucl.2016.04.010_bib9","first-page":"1793","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11934-014-0441-2","article-title":"Impact of alpha blocker, 5-alpha reductase inhibitors and combination therapy on sexual function","volume":"15","author":"Welliver","year":"2014","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.ucl.2016.04.010_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group","volume":"37","author":"van Kerrebroeck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib12","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.pcan.4500367","article-title":"The pharmacological perspective: role for the sympathetic nervous system in micturition and sexual function","volume":"2","author":"Andersson","year":"1999","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2016.04.010_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1442-2042.2008.02136.x","article-title":"Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography","volume":"15","author":"Nagai","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1442-2042.2006.01535.x","article-title":"Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission","volume":"13","author":"Hisasue","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib15","first-page":"2185","article-title":"Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers","volume":"5","author":"Kobayashi","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib16","first-page":"261","article-title":"Effect of drugs interacting with adrenoreceptors and muscarinic receptors in the epididymal and prostatic parts of the human isolated vas deferens","volume":"5","author":"Hedlund","year":"1985","journal-title":"J\u00a0Auton Pharmacol"},{"key":"10.1016\/j.ucl.2016.04.010_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjp.0701485","article-title":"Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions","volume":"122","author":"Moriyama","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.ucl.2016.04.010_bib18","first-page":"1828","article-title":"Change in sexual function in men with lower urinary tract symptoms\/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy","volume":"191","author":"Fwu","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1464-410X.2005.05347.x","article-title":"Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction","volume":"95","author":"van Moorselaar","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1464-410X.2005.05962.x","article-title":"ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice","volume":"97","author":"Elhilali","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000019996","article-title":"Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"H\u00f6fner","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib23","first-page":"1701","article-title":"A\u00a0second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group","volume":"160","author":"Narayan","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urology.2013.03.026","article-title":"Effect of selective alpha-blocker tamsulosin on erectile function in patients with lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"82","author":"Shelbaia","year":"2013","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2016.04.010_bib25","article-title":"Tamsulosin for benign prostatic hyperplasia","author":"Wilt","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ucl.2016.04.010_bib26","first-page":"857","volume":"10","author":"Giuliano","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bju.12712","article-title":"A\u00a0pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)","volume":"114","author":"Novara","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","article-title":"Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men","volume":"98","author":"Kawabe","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib29","first-page":"1529","article-title":"Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11255-011-9949-2","article-title":"Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia","volume":"43","author":"Karadag","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ucl.2016.04.010_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","article-title":"Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe","volume":"59","author":"Chapple","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib32","first-page":"1554","article-title":"Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis","volume":"11","author":"Gacci","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib33","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib34","first-page":"S122","article-title":"Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies","volume":"189","author":"Marks","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group","volume":"335","author":"Lepor","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MED.0000000000000116","article-title":"5-Alpha reductase deficieny: a 40-year retrospective review","volume":"21","author":"Okeigwe","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ucl.2016.04.010_bib37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia","volume":"327","author":"Gormley","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib38","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1210\/endo.138.8.5310","article-title":"Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat","volume":"138","author":"Schirar","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.ucl.2016.04.010_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14740338.2013.742885","article-title":"Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation","volume":"12","author":"Gur","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ucl.2016.04.010_bib40","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/jcem.87.4.8138","article-title":"The\u00a0effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study","volume":"87","author":"Kunelius","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2016.04.010_bib41","first-page":"77","article-title":"Erectile function in elderly: role of androgens","volume":"26","author":"Foresta","year":"2003","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.ucl.2016.04.010_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pnpbp.2004.11.001","article-title":"Steroids, neuroactive steroids and neurosteroids in psychopathology","volume":"29","author":"Dubrovsky","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.ucl.2016.04.010_bib43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABA(A) receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.ucl.2016.04.010_bib44","first-page":"2598","article-title":"Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious\/depressive symptomatology","volume":"10","author":"Melcangi","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2165\/00003088-199630010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of finasteride","volume":"30","author":"Steiner","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ucl.2016.04.010_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/pcan.2008.56","article-title":"5alpha-reductase inhibitor treatment of prostatic diseases: background and practical implications","volume":"12","author":"D\u00f6rsam","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2016.04.010_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.urology.2004.01.001","article-title":"Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia","volume":"63","author":"Roehrborn","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/11593750-000000000-00000","article-title":"Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension","volume":"32","author":"Na","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ucl.2016.04.010_bib50","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2016.04.010_bib51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2004.05.008","article-title":"Efficacy and safety of the long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia","volume":"46","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib52","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-4295(98)00094-6","article-title":"Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group","volume":"51","author":"Marberger","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia","volume":"39","author":"Kaufman","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ucl.2016.04.010_bib55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss","volume":"40","author":"Leyden","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ucl.2016.04.010_bib56","first-page":"150","article-title":"Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss","volume":"13","author":"Whiting","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ucl.2016.04.010_bib57","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0149-2918(95)80073-5","article-title":"Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study","volume":"17","author":"Byrnes","year":"1995","journal-title":"Clin Ther"},{"key":"10.1016\/j.ucl.2016.04.010_bib58","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(02)02548-7","article-title":"Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia","volume":"61","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0149-2918(97)80113-0","article-title":"Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study","volume":"19","author":"Tenover","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.ucl.2016.04.010_bib60","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa030660","article-title":"The\u00a0influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia","volume":"338","author":"McConnell","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib62","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study)","volume":"155","author":"Nickel","year":"1996","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ucl.2016.04.010_bib63","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the enlarged prostate international comparator study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib64","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/jc.2006-2203","article-title":"The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men","volume":"92","author":"Amory","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2016.04.010_bib65","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","article-title":"Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia","volume":"61","author":"Wessels","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib66","first-page":"1708","article-title":"Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib67","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/en.2006-1079","article-title":"Characterization and functional role of androgen-dependent PDE5 activity in the bladder","volume":"148","author":"Filippi","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ucl.2016.04.010_bib68","first-page":"271","article-title":"Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study","volume":"9","author":"Egerdie","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib69","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1176\/ajp.139.9.1193","article-title":"Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants","volume":"139","author":"Gross","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ucl.2016.04.010_bib70","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.144.9.1243b","article-title":"Reversal by bethanechol of imipramine-induced ejaculatory dysfunction","volume":"144","author":"Segraves","year":"1987","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.ucl.2016.04.010_bib71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1745-7262.2006.00088.x","article-title":"Erectile dysfunction after transurethral prostatectomy for lower urinary tract symptoms: results from a center with over 500 patients","volume":"8","author":"Poulakis","year":"2006","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ucl.2016.04.010_bib72","first-page":"1682","article-title":"Clinically and statistically significant changes seen in sham surgery arms of randomized, controlled benign prostatic hyperplasia surgery trials","volume":"194","author":"Welliver","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib73","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.urology.2011.11.084","article-title":"National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008)","volume":"79","author":"Malaeb","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2016.04.010_bib74","first-page":"1206","article-title":"Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study","volume":"164","author":"Arai","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib75","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1464-410X.2007.07042.x","article-title":"Bipolar plasmakinetic technology for the treatment of symptomatic benign prostatic hyperplasia: evidence beyond marketing hype","volume":"100","author":"Autorino","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib76","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/end.2008.0192","article-title":"Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP","volume":"22","author":"Issa","year":"2008","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.ucl.2016.04.010_bib77","first-page":"1817","article-title":"Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial","volume":"175","author":"Briganti","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib78","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2007.01.088","article-title":"Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome","volume":"52","author":"Muntener","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ijir.2009.56","article-title":"Effect of transurethral resection of the prostate on erectile function: a prospective comparative study","volume":"22","author":"Jaidane","year":"2010","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.ucl.2016.04.010_bib80","first-page":"1354","article-title":"Erectile dysfunction following transurethral resection of the prostate","volume":"156","author":"Soderdahl","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJM199501123320202","article-title":"A\u00a0comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia: the Veterans Affairs Cooperative Study Group on transurethral resection of the prostate","volume":"332","author":"Wasson","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1464-410X.1993.tb00686.x","article-title":"The prostatron transurethral microwave device in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia","volume":"72","author":"Kirby","year":"1993","journal-title":"Br J Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib83","first-page":"97","article-title":"High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group","volume":"156","author":"de la Rosette","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib84","first-page":"486","article-title":"Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection","volume":"161","author":"Francisca","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib85","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/08927790360587432","article-title":"Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months","volume":"17","author":"Cimentepe","year":"2003","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.ucl.2016.04.010_bib86","first-page":"2161","article-title":"The\u00a0prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study","volume":"190","author":"Roehrborn","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib87","first-page":"279","article-title":"Treatment of LUTS Secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift","volume":"11","author":"McVary","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib88","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.10.031","article-title":"Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"67","author":"Perera","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib89","first-page":"7772","article-title":"Three year results of the prostatic urethral L.I.F.T. study","volume":"22","author":"Roehrborn","year":"2015","journal-title":"Can J Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1464-410X.2003.04072.x","article-title":"Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study","volume":"91","author":"Gacci","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib91","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2006.04.002","article-title":"A\u00a0randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years","volume":"50","author":"Wilson","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2016.04.010_bib92","first-page":"408","article-title":"Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years","volume":"109","author":"Gilling","year":"2011","journal-title":"BJU\u00a0Int"},{"key":"10.1016\/j.ucl.2016.04.010_bib93","first-page":"1701","article-title":"Influence of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate on erectile function: a short-term follow-up study","volume":"4","author":"Paick","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib94","first-page":"2669","article-title":"Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hyperplasia","volume":"5","author":"Kavoussi","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2016.04.010_bib95","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1089\/end.2014.0170","article-title":"A\u00a0prospective study on the effect of photoselective vaporization of prostate by 120-W high-performance system laser on sexual function","volume":"28","author":"Kumar","year":"2014","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.ucl.2016.04.010_bib96","first-page":"1363","article-title":"Prospective, multidimensional evaluation of sexual disorders in men after laser photovaporization of the prostate","volume":"10","author":"Terrasa","year":"2013","journal-title":"J\u00a0Sex Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014316300118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014316300118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:32:08Z","timestamp":1758807128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014316300118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0094014316300118"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2016.04.010","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2016.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}